RXRX
Recursion Pharmaceuticals IncNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Anti-Quality Mid Cap
$3.84-4.36%
Close Oct 13, 2026
- Market cap
- $2.03B
- 1 month
- +12.5%
- 3 months
- +15.9%
- 1 year
- -27.9%
- 52-week range
- $2.84$6.79
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.23Quarter to Sep 30, 2026 · 6 analysts · revenue $13.04M
- Short interest
- 30.5% of float157.9M shares · settled Sep 30, 2026 · -11.6% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $54.86M
- Net income
- -$518.89M
- Free cash flow
- -$354.27M
- Book value
- $915M
- Total debt
- $61.89M
- P/E
- —
- Price / sales
- 37.1×
- Price / book
- 2.2×
- FCF yield
- -17.4%
- Net margin
- -945.9%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if RXRX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
46 top institutions tracked
as of 2026-Q2 (filed 2026-09-23)
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 7 days ago
Red flags: 19
Largest 13-F holders · Q2 2026
344 filers reported a long position in RXRX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $184.6M | 50.3M | +16.5% |
| ARK Investment Management LLC | $151.7M | 41.3M | +2.8% |
| STATE STREET CORP | $127.4M | 34.7M | +21.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $114.3M | 31.1M | +36.8% |
| BAILLIE GIFFORD & CO | $86.2M | 23.5M | -0.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $83.6M | 22.8M | +2.3% |
| GEODE CAPITAL MANAGEMENT, LLC | $50.7M | 13.8M | +12.6% |
| SOFTBANK GROUP CORP. | $50M | 13.6M | Unchanged |
| MIC Capital Management UK LLP | $35.4M | 9.6M | 0% |
| UBS Group AG | $32.8M | 8.9M | +75.4% |
Get the Full Analysis for RXRX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.